Ischemic Stroke is an indication for drug development with over 210 pipeline drugs currently active. According to GlobalData, preregistered drugs for Ischemic Stroke have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Ischemic Stroke compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ischemic Stroke overview
Ischemic stroke occurs when there is a disruption of blood flow to a part of the brain, leading to a lack of oxygen and nutrients. This can happen when a blood vessel that supplies blood to the brain becomes blocked or narrowed, often due to the formation of a blood clot or plaque buildup within the vessel. The blockage can occur within the blood vessels of the brain itself (cerebral arteries) or can be due to emboli, which are clots or debris that travel from other parts of the body to the brain. Ischemic strokes are the most common type of stroke, accounting for the majority of stroke cases. There are two main subtypes of ischemic stroke: 1.Thrombotic stroke occurs when a blood clot (thrombus) forms within one of the arteries that supply blood to the brain. The clot may develop in an already narrowed or atherosclerotic artery. 2. Embolic stroke happens when a blood clot or other material (an embolus) forms in another part of the body, such as the heart or a large artery, and then travels to the brain through the bloodstream, causing a blockage in a smaller blood vessel in the brain.
For a complete picture of PTSR and LoA scores for drugs in Ischemic Stroke, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
